Prognostic factors in 408 elderly lung cancer patients more than 70 years old

Chinese Journal of Lung Cancer

Volumn 14, Issue 6, 2011, Pages 502-506

  Zheng, Hua ^a   Tong, Li ^a   Hu, Ying ^a   Wu, Weihua ^a   Zhang, Hongmei ^a   Li, Baolan ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Geriatrics; Lung neoplasms; Prognosis

Indexed keywords

AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; COMPLICATION; EFFUSION; GENDER; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; PROGNOSIS; REGRESSION ANALYSIS;

EID: 79958714789     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2011.06.05     Document Type: Article

References (22)

1. ingo PA, Cardinez CJ, Landis SH, et al. Long-term trends in cancer mortality in the United States, 1930-1998. Cancer, 2003, 97(12 Suppl): 3133-3275.
2. Gridelli C. Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer? Lung Cancer, 2002, 38 (Suppl 2): S45-S50.
3. Professional Committee of Chinese Anti-Cancer Association of lung cancer ed. 2010 China clinical guide to lung cancer. 1st ed. Beijing: People's Health Publishing House, 2010. 7.
4. Meriggi F, Zaniboni A. Non-small-cell lung cancer in the elderly. Crit Rev Oncol Hematol, 2006, 57(2): 183-190.
5. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst, 2002, 94(3): 173-181.
6. Wakelee HA, Wang W, Schiller JH, et al. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol, 2006, 1(5): 441-446.
7. Belani CP, Fossella F. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer, 2005, 104(12): 2766-2774.
8. Chansky K, Sculier JP, Crowley JJ, et al. The International Association for the Study of Lung Cancer Staging Project. Prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. International Staging Committee and Participating Institutions. Chin J Lung Cancer, 2010, 13(1): 9-18.
9. Kefeli U, Kaya S, Ustaalioglu BO, et al. Prognostic factors in elderly patients with non-small cell lung cancer: a two-center experience. Med Oncol, 2010 Mar 31. [Epub ahead of print]
10. Zhang ZJ, Cheng G, Sun JK, et al. Survival analysis of non-small cell lung cancer in patients aged 70 and over. Chin J Lung Cancer, 2008, 11(2): 231-235.
11. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest, 2009, 136(1): 260-271.
12. Gornik HL, Gerhard-Herman M, Beckman JA. Abnormal cytology predicts poor prognosis in cancer patients with pericardial effusion. J Clin Oncol, 2005, 23(22): 5211-5216.
13. Holdener EE, Ryser DH, Schaermeli K, et al. Malignant pericardial effusion-a sign of unfavorable prognosis? Schweiz Med Wochenschr, 1986, 116(12): 366-370.
14. Chen YM, Perng RP, Shih JF, et al. A phase II randomized study of vinorelbine alone or with cisplatin against chemo-nae inoperable non-small cell lung cancer in the elderly. Lung Cancer, 2008, 61(2): 214-219.
15. Lou GY, Li T, Gu CP, et al. Efficacy study of single-agent gemcitabine versus gemcitabine plus carboplatin in untreated elderly patients with stage IIIb/IV non-small-cell lung cancer. Zhonghua Yi Xue Za Zhi, 2010, 90(2): 100-102.
16. Camerini A, Valsuani C, Mazzoni F, et al. Phase II trial of single-agent oral vinorelbine in elderly (> or =70 years) patients with advanced non-smallcell lung cancer and poor performance status. Ann Oncol, 2010, 21(6): 1290-1295.
17. Quoix E, Breton JL, Ducoloné A, et al. First line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule. Lung Cancer, 2005, 47(3): 405-412.
18. Rossi D, Dennetta D, Ugolini M, et al. Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study. Clin Lung Cancer, 2008, 9(5): 280-284.
19. Malani AK, Abou-Jawde RM, Singh J, et al. Docetaxel as monotherapy in the treatment of advanced non-small-cell lung cancer in elderly patients. J Clin Oncol, 2007, 25(9): 1143-1144.
20. Weiss GJ, Langer C, Rosell R, et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol, 2006, 4(27): 4405-4444.
21. Leong SS, Toh CK, Lim WT, et al. A randomized phase II trial of singleagent gemcitabine, vinorelbine, or docetaxel in patients with advanced nonsmall cell lung cancer who have poor performance status and/or are elderly. J Thorac Oncol, 2007, 2(3): 230-236.
22. Quoix EA, Oster J, Westeel V, et al. Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC). 2010 ASCO Annual Meeting, Abstract No: 2.